# advanced endometrial cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/advanced-endometrial-cancer

> 2 upcoming FDA catalysts in advanced endometrial cancer: TYVYT® (sintilimab, HCM) on Jan to Apr 2029 (topline data readout); TYVYT® (sintilimab, HCM) on January 2029 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2025 | [KANJINTI® (trastuzumab) trial start](https://sec-api.dev/pdufa/trastuzumab) | BNTX | advanced endometrial cancer | completed | "-In September 2025, the first patient was dosed in a Phase 3 trial (NCT06340568) to evaluate trastuzumab pamirtecan compared to investigator's choice of chemotherapy in patients with advanced endometrial cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000065/bnt_2025q3ex99x1quarterlyr.htm)) |
| late 2026 | [Faeth Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/fth/catalysts) | FTH | advanced endometrial cancer | scheduled | "Topline Phase 2 data in patients with advanced endometrial cancer expected in second half 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1829802/000119312526225323/d125741dex991.htm)) |
| Jan to Apr 2029 | [TYVYT® (sintilimab) topline data readout](https://sec-api.dev/pdufa/sintilimab) | HCM | Advanced Endometrial Cancer | scheduled | "NCT06584032 (Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-08 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06584032)) |
| January 2029 | [TYVYT® (sintilimab) primary completion](https://sec-api.dev/pdufa/sintilimab) | HCM | Advanced Endometrial Cancer | scheduled | "NCT06584032 (Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-08 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06584032)) |

## Drugs

- [KANJINTI® (trastuzumab)](https://sec-api.dev/pdufa/trastuzumab) (BNTX)
- [TYVYT® (sintilimab)](https://sec-api.dev/pdufa/sintilimab) (HCM)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/advanced-endometrial-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "advanced endometrial cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/advanced-endometrial-cancer

```bibtex
@misc{secapidev_indications_advanced_endometrial_cancer_20261116,
  title        = {advanced endometrial cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/advanced-endometrial-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_advanced_endometrial_cancer_20261116","title":"advanced endometrial cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/advanced-endometrial-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
